Biopharmaceutical Contract Manufacturing Market Is Likely to Grow at an Impressive CAGR of 10.6% by 2027: Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies
A new study by FMI titled 'Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027', has listed out the key points being considered by Biopharmaceutical contract manufacturing companies to emerge and stay sustainably profitable in the long run. The North American Biopharmaceutical contract manufacturing market is expected to expand at a CAGR of close to 10%, and is expected to remain as a main sink market for revenues, as most of the biopharmaceutical contract manufacturing facilities are...
View full press release